Monogram Technologies (MGRM) Q3 2024 earnings summary

Executive summary

• Ended Q3 2024 with $16.6 million in cash and a $1.2 million monthly cash run rate, supported by a $13 million Series D Preferred Stock offering and $4.3 million from an at-the-market equity program.

• Focused on commercializing a fully autonomous saw-cutting robot for orthopedic surgery, with all employees dedicated to R&D and regulatory milestones.

• Submitted first 510(k) application to the FDA in July 2024, received an Additional Information Request in September, and prepared a detailed response for a December Q-Sub meeting.

• No product revenue recognized for the nine months ended September 30, 2024, as commercialization is pending regulatory approvals.

• Anticipates significant milestones in 2025–2026, including potential product launch and expansion into international markets.

Financial highlights

• Net loss for Q3 2024 was $5.0 million, with a year-to-date net loss of $12.1 million, and operating expenses for Q3 2024 rose 37% year-over-year to $5.1 million.

• Operating cash flow year-to-date is $10.9 million, with no traditional debt and minimal short-term warrant obligations.

• Cash and cash equivalents were $16.6 million as of September 30, 2024, up from $13.6 million at year-end 2023.

• Total stockholders' equity increased to $17.4 million from $13.4 million at December 31, 2023.

• No revenue was reported for the three or nine months ended September 30, 2024.

Outlook and guidance

• Management believes current cash balances and available capital under equity programs are sufficient to meet near-term capital needs and support operations for at least 12 months.

• Confident in meeting short-term milestones with current funding; potential to accelerate development if additional capital or strategic partnerships are secured.

• OUS clinical trial in India expected to begin in 2025, with live patient surgeries anticipated next year.

• FDA clearance decision expected by Q2 2025 if the full review period is used; commercialization could begin in 2025 or 2026 depending on regulatory outcomes.

• Plans to expand into other large international markets, including Indonesia, South America, and the Middle East.